Estée Lauder Companies Inc (EL) Report Interpretation

Overview

This earnings follow-up argues that Estée Lauder’s turnaround is gaining credibility: fourth-quarter growth broadened, margins exceeded expectations, and FY27 margin guidance improved. Morgan Stanley nonetheless maintains an Equal-weight rating because the stock’s valuation already reflects a meaningful recovery and durable share gains remain to be demonstrated.

Core views

Estée Lauder delivered a stronger-than-expected FQ4 in what Morgan Stanley characterizes as a light seasonal quarter, with adjusted EPS of $0.39 versus $0.32 consensus, a 21% beat. Organic sales growth (OSG) was 5%, 200 bps above consensus and the company’s highest growth since FY22. Gross profit was 6.3% above consensus and gross margin was roughly 230 bps above consensus, including about 100 bps from tariff refunds. SG&A as a percentage of sales was about 160 bps above consensus, but operating profit still exceeded consensus by 16%. The $0.07 EPS beat included a $0.07 tariff-refund benefit, partly offset by an approximately $0.05 Middle East headwind. Morgan Stanley’s main positive takeaway is that growth became substantially broader across regions and categories. Asia/Pacific OSG was 520 bps above consensus and the Americas was 390 bps above consensus; Mainland China was 85 bps above consensus while EUKEM was 35 bps below. Skin Care and Fragrance exceeded consensus by 433 bps and 489 bps, respectively, whereas Makeup and Hair Care lagged by 46 bps and 159 bps. After adjusting for an $18m one-time Americas gift-card benefit and an approximately 2-point Middle East headwind in EUKEM, the Americas returned to growth at 5%, or about 3% excluding the gift-card item, versus a 1% year-to-date decline. APAC accelerated to 9% from 3% through FQ3. Skin Care and Makeup improved by 400 bps and 300 bps versus their first-nine-month trends, and Fragrance remained strong. The report sees support for continued momentum into the first half of FY27. Management expects OSG to be stronger in the first half than the second because innovation is weighted to the first half, travel-retail shipments should rise, and comparisons ease. Global travel retail returned to positive growth in June and July for the first time in three years, led by double-digit Hainan growth in FQ4. Innovation represented 23% of FY26 sales and is expected to rise another 200-250 bps as a share of sales in FY27, led by Skin Care. Management retained 3-5% FY27 OSG guidance, and Morgan Stanley has greater confidence in that range after FQ4 exited at 5% OSG. Margin recovery is also advancing faster than previously expected. FY26 adjusted operating margin finished at 11.2%, above the prior 10.7-11.0% outlook, and FY27 adjusted operating-margin guidance increased to 12.7-13.5% from 12.5-13.0%. Morgan Stanley attributes the better range to the stronger FY26 base, additional FY27 SG&A optimization opportunities, and modest gross-margin expansion. Profit Recovery and Growth Plan (PRGP) gross benefits are now expected at approximately $1.2bn, the high end of the prior approximately $1.0-1.2bn range. The firm raised its FY27 and FY28 EPS estimates by 2% and 1%, respectively, and expects potentially larger positive consensus revisions because its FY28 EPS forecast had been 5% above consensus before the results. A counterpoint is cash flow: FY27 operating-cash-flow guidance of $1.3-1.4bn is below roughly $1.8bn in FY26 and the $2.0bn consensus despite the stronger earnings outlook. The company attributes the decline to higher restructuring cash payments and increased working-capital requirements needed to support growth; most restructuring-related cash payments should be behind it after FY27. Morgan Stanley raised its price target to $102 from $90, based on approximately 25x FY28 EPS and a recovery in operating margin to 15%, supported primarily by PRGP savings and margin recovery. Yet it keeps Equal-weight. The report argues that the stock, after a 16% move following results versus 0.2% for the S&P 500, already trades at 24x its above-consensus FY28 EPS forecast. It therefore wants more sustained evidence of turnaround execution and durable share gains. The firm also notes that management downplayed transformational M&A, reducing a near-term overhang after Puig discussions, though some M&A risk remains because of Estée Lauder’s historical interest in larger deals and flexibility in the definition of transformational.

Analysis framework

Morgan Stanley compares FQ4 earnings, organic sales growth, gross margin, operating profit, and EPS against consensus; then tests whether growth improved across regions and product categories after adjusting for one-time items. It links FY27 guidance, innovation, travel-retail trends, PRGP savings, and SG&A optimization to its earnings and margin outlook, while weighing lower cash-flow guidance and execution risks. Its $102 price target applies an approximately 25x multiple to FY28 EPS.

Methodology notes

• Industry AnalysisVolume-price decomposition

  Organic sales growth analysis by geography and product category, adjusted for one-time regional items.

  The report uses OSG to distinguish underlying sales momentum from other effects, compares it with consensus, and assesses whether improvement is broad enough to support FY27 guidance.

• Valuation methodsP/E and PEG Valuation

  Price target based on approximately 25x FY28 EPS.

  Morgan Stanley values the shares by applying a forward earnings multiple, justified by EPS expansion from PRGP savings and operating-margin recovery.

• Corporate Fundamentals and FinanceFree cash flow analysis

  Operating cash flow assessed alongside earnings guidance, restructuring payments, and working-capital needs.

  The report highlights that stronger profit expectations do not translate into higher FY27 operating cash flow because of near-term cash restructuring and growth-related working-capital demands.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Estée Lauder Companies Inc (EL)

  Primary covered company; benefits from broader organic-sales growth and PRGP-driven margin recovery.

  Strengths

  FQ4 OSG beat consensus, regional and category growth broadened, FY27 operating-margin guidance increased, and travel retail returned to positive growth in June and July.

  Weaknesses

  FY27 operating cash flow is expected to decline because of restructuring cash payments and higher working-capital needs.

  Comparison

  FQ4 EPS of $0.39 exceeded $0.32 consensus; OSG of 5% was 200 bps above consensus.

  Risks

  Softer prestige-beauty demand, slower travel-retail improvement, weaker or reversing share gains, execution challenges with Beauty Reimagined, competitive pricing, and M&A uncertainty.

Key data

• FQ4 adjusted EPS$0.39 vs $0.32 consensus21% beat in a quarter representing 16% of fiscal-year EPS.
• FQ4 organic sales growth+5%200 bps above consensus; highest growth since FY22.
• FY27 OSG guidance+3-5%Unchanged; management expects the first half to be stronger than the second.
• FY27 adjusted operating-margin guidance12.7%-13.5%Raised from the preliminary 12.5%-13.0% range.
• FY26 adjusted operating margin11.2%Above the prior 10.7%-11.0% outlook.
• PRGP gross benefits~$1.2bnAt the high end of the prior approximately $1.0-1.2bn range.
• FY27 operating cash flow guidance$1.3bn-$1.4bnBelow FY26’s approximately $1.8bn and $2.0bn consensus.
• Price target$102.00Raised from $90.00 and based on approximately 25x FY28 EPS.

Impact & implications

The report views the quarter as evidence that Estée Lauder’s recovery is becoming broader and that PRGP savings can support faster margin and EPS recovery. However, it considers this improving outlook substantially reflected in the share valuation, while cash conversion weakens in FY27 and the durability of share gains, travel-retail recovery, and premium-beauty demand remain unresolved.

Risks

• Premium-category and discretionary-beauty demand could weaken following the Iran conflict.
• Travel-retail improvement could slow or stall amid macroeconomic and geopolitical pressure.
• Market-share gains could prove slower, reverse, or lack durability.
• Execution on Beauty Reimagined could be more difficult than expected.
• Competitive pricing could pressure performance.
• Larger M&A risk remains despite management’s comments against transformational deals.

What to watch

• Whether first-half FY27 OSG outpaces the second half as management expects.
• Travel-retail sales, including China and Hainan trends, and the durability of its return to positive growth.
• The breadth and persistence of market-share gains across regions and beauty categories.
• Delivery of PRGP savings, SG&A optimization, and operating-margin recovery.
• Prestige-beauty demand, pricing, product mix, and normalization of inventory.
• The November 13, 2026 annual shareholders meeting and November 17, 2026 catalyst-calendar date.